Questions with no answer at all. Not questions with no accepted answer — those are elsewhere.
What I am working with: SURMOUNT-OSA · 50 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
The case in front of me: 10 mg · 2.5 mL · 0.9% sodium chloride · mazdutide. I want to decide this in advance so that I am not deciding it under pressure later. Assume…
The specifics, since they change the answer: 4 mg · ten weeks · reflux. I understand the observation; what I do not understand is the mechanism behind it. I have read…
The specifics, since they change the answer: tirzepatide · three weeks · room temperature. I understand the observation; what I do not understand is the mechanism…
The method section is present, which is unusual enough that I want to make use of it. I have read the primary source rather than the summary, which has left me with…
What I am working with: REDEFINE-1 · 4 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I…
The material is still sealed, so I have not committed to anything yet. This is a planning question. I know what my options are; I do not know how to weigh them. What…
What I have: 95.2% · purity figure. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
For reference: Hangzhou · the Netherlands. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
What I have: mazdutide · sixteen weeks · room temperature. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can…
Numbers first: cagrilintide · 1 mg/mL. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me which work…
Concretely: survodutide · survodutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I can…
The specifics, since they change the answer: SURMOUNT-1 · 5 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I…
I have the full paper rather than the abstract, and the supplementary appendix. I can predict the outcome but I cannot explain it, which means I will get the next…
What I have: a GLP-1 receptor agonist · five days. This should be a straightforward calculation and I keep getting two different answers. The numbers are arbitrary;…
Concretely: ecnoglutide · sterile water for injection. I want to know whether this is a real physical effect or an artefact of how it is measured. What prompted the…
For reference: FLOW · survodutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
Stated plainly: FGP · Hangzhou · the Netherlands. I would like to set this up properly once, rather than adjust it repeatedly. My budget is real but not tight, and my…
What I have: mazdutide · purity figure. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
The particulars: SUSTAIN-6 · early satiety. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
For reference: oral semaglutide · minus 20 °C · fourteen days. I am at the decision point and I would rather think it through than improvise. I would rather spend…
Numbers first: STEP 4 · orforglipron. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists…
Setup, so nobody has to ask: Janoshik · 98.2%. This is not behaving the way I expected and I want to understand the discrepancy before I act on it. I have…
The case in front of me: TFC · oral semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…